Contributing factors related to efficacy of the dipeptidyl peptidase-4 inhibitor sitagliptin in Japanese patients with type 2 diabetes
Gespeichert in:
| Veröffentlicht in: | Diabetes research and clinical practice 2012-02, Vol.95 (2), p.e27-e28 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | e28 |
|---|---|
| container_issue | 2 |
| container_start_page | e27 |
| container_title | Diabetes research and clinical practice |
| container_volume | 95 |
| creator | Nomiyama, Takashi Akehi, Yuko Takenoshita, Hiromasa Nagaishi, Ryoko Terawaki, Yuichi Nagasako, Hisahiro Kudo, Tadachika Kodera, Takehiko Kobayashi, Kunihisa Urata, Hidenori Yanase, Toshihiko |
| description | |
| doi_str_mv | 10.1016/j.diabres.2011.08.016 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_919226555</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S016882271100461X</els_id><sourcerecordid>919226555</sourcerecordid><originalsourceid>FETCH-LOGICAL-c419t-37613906c778740b7cb8399d1026554ea784d03409b891b12eba217e28d18da3</originalsourceid><addsrcrecordid>eNqFUsmO1DAQtRCIaQY-AeQbpwSXs9kXEGqxaiQOzIGb5aUy7SadBNsB5Qf4bhy64cCFk0vPr7b3ipCnwEpg0L44ls5rEzCWnAGUTJQZvUd2IDpeCM67-2SXEfE7viKPYjwyxtqqbh6SKw5CSgl8R37upzEFb5bkxzvaa5umEGnAQSd0NE0U-95bbVc69TQdkDo_45y8Wwd6DnTEoqZ-PHjjczKNPum7weevMaP0o571iBHprJPHMUX6w6cDTeuMlNNtB0wYH5MHvR4iPrm81-T27Zvb_fvi5tO7D_vXN4WtQaai6lqoJGtt14muZqazRlRSOmC8bZoadSdqx6qaSSMkGOBoNIcOuXAgnK6uyfNz2TlM3xaMSZ18tDgMecRpiUqC5FulJjObM9OGKcaAvZqDP-mwKmBqM0Ad1cUAtRmgmFAZzXnPLh0Wc0L3N-uP4pnw6kzAvOZ3j0FFm3Wx6HxAm5Sb_H9bvPyngh38mE0avuKK8TgtYcwaKlCRK6Y-b1ewHQEAY3ULX6pfPV2v8Q</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>919226555</pqid></control><display><type>article</type><title>Contributing factors related to efficacy of the dipeptidyl peptidase-4 inhibitor sitagliptin in Japanese patients with type 2 diabetes</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><creator>Nomiyama, Takashi ; Akehi, Yuko ; Takenoshita, Hiromasa ; Nagaishi, Ryoko ; Terawaki, Yuichi ; Nagasako, Hisahiro ; Kudo, Tadachika ; Kodera, Takehiko ; Kobayashi, Kunihisa ; Urata, Hidenori ; Yanase, Toshihiko</creator><creatorcontrib>Nomiyama, Takashi ; Akehi, Yuko ; Takenoshita, Hiromasa ; Nagaishi, Ryoko ; Terawaki, Yuichi ; Nagasako, Hisahiro ; Kudo, Tadachika ; Kodera, Takehiko ; Kobayashi, Kunihisa ; Urata, Hidenori ; Yanase, Toshihiko ; members of CHAT ; CHAT</creatorcontrib><identifier>ISSN: 0168-8227</identifier><identifier>EISSN: 1872-8227</identifier><identifier>DOI: 10.1016/j.diabres.2011.08.016</identifier><identifier>PMID: 21899912</identifier><language>eng</language><publisher>Ireland: Elsevier Ireland Ltd</publisher><subject>Adult ; Aged ; Asia - epidemiology ; Asian Continental Ancestry Group - statistics & numerical data ; Biomarkers - blood ; Body Mass Index ; Diabetes Mellitus, Type 2 - blood ; Diabetes Mellitus, Type 2 - drug therapy ; Diabetes Mellitus, Type 2 - physiopathology ; Diabetic Nephropathies - blood ; Diabetic Nephropathies - drug therapy ; Diabetic Nephropathies - physiopathology ; Dipeptidyl-Peptidase IV Inhibitors - therapeutic use ; Endocrinology & Metabolism ; Female ; Glycated Hemoglobin A - metabolism ; Humans ; Male ; Middle Aged ; Pyrazines - therapeutic use ; Sitagliptin Phosphate ; Treatment Outcome ; Triazoles - therapeutic use</subject><ispartof>Diabetes research and clinical practice, 2012-02, Vol.95 (2), p.e27-e28</ispartof><rights>Elsevier Ireland Ltd</rights><rights>2011 Elsevier Ireland Ltd</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c419t-37613906c778740b7cb8399d1026554ea784d03409b891b12eba217e28d18da3</citedby><cites>FETCH-LOGICAL-c419t-37613906c778740b7cb8399d1026554ea784d03409b891b12eba217e28d18da3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S016882271100461X$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65534</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21899912$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Nomiyama, Takashi</creatorcontrib><creatorcontrib>Akehi, Yuko</creatorcontrib><creatorcontrib>Takenoshita, Hiromasa</creatorcontrib><creatorcontrib>Nagaishi, Ryoko</creatorcontrib><creatorcontrib>Terawaki, Yuichi</creatorcontrib><creatorcontrib>Nagasako, Hisahiro</creatorcontrib><creatorcontrib>Kudo, Tadachika</creatorcontrib><creatorcontrib>Kodera, Takehiko</creatorcontrib><creatorcontrib>Kobayashi, Kunihisa</creatorcontrib><creatorcontrib>Urata, Hidenori</creatorcontrib><creatorcontrib>Yanase, Toshihiko</creatorcontrib><creatorcontrib>members of CHAT</creatorcontrib><creatorcontrib>CHAT</creatorcontrib><title>Contributing factors related to efficacy of the dipeptidyl peptidase-4 inhibitor sitagliptin in Japanese patients with type 2 diabetes</title><title>Diabetes research and clinical practice</title><addtitle>Diabetes Res Clin Pract</addtitle><subject>Adult</subject><subject>Aged</subject><subject>Asia - epidemiology</subject><subject>Asian Continental Ancestry Group - statistics & numerical data</subject><subject>Biomarkers - blood</subject><subject>Body Mass Index</subject><subject>Diabetes Mellitus, Type 2 - blood</subject><subject>Diabetes Mellitus, Type 2 - drug therapy</subject><subject>Diabetes Mellitus, Type 2 - physiopathology</subject><subject>Diabetic Nephropathies - blood</subject><subject>Diabetic Nephropathies - drug therapy</subject><subject>Diabetic Nephropathies - physiopathology</subject><subject>Dipeptidyl-Peptidase IV Inhibitors - therapeutic use</subject><subject>Endocrinology & Metabolism</subject><subject>Female</subject><subject>Glycated Hemoglobin A - metabolism</subject><subject>Humans</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Pyrazines - therapeutic use</subject><subject>Sitagliptin Phosphate</subject><subject>Treatment Outcome</subject><subject>Triazoles - therapeutic use</subject><issn>0168-8227</issn><issn>1872-8227</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFUsmO1DAQtRCIaQY-AeQbpwSXs9kXEGqxaiQOzIGb5aUy7SadBNsB5Qf4bhy64cCFk0vPr7b3ipCnwEpg0L44ls5rEzCWnAGUTJQZvUd2IDpeCM67-2SXEfE7viKPYjwyxtqqbh6SKw5CSgl8R37upzEFb5bkxzvaa5umEGnAQSd0NE0U-95bbVc69TQdkDo_45y8Wwd6DnTEoqZ-PHjjczKNPum7weevMaP0o571iBHprJPHMUX6w6cDTeuMlNNtB0wYH5MHvR4iPrm81-T27Zvb_fvi5tO7D_vXN4WtQaai6lqoJGtt14muZqazRlRSOmC8bZoadSdqx6qaSSMkGOBoNIcOuXAgnK6uyfNz2TlM3xaMSZ18tDgMecRpiUqC5FulJjObM9OGKcaAvZqDP-mwKmBqM0Ad1cUAtRmgmFAZzXnPLh0Wc0L3N-uP4pnw6kzAvOZ3j0FFm3Wx6HxAm5Sb_H9bvPyngh38mE0avuKK8TgtYcwaKlCRK6Y-b1ewHQEAY3ULX6pfPV2v8Q</recordid><startdate>20120201</startdate><enddate>20120201</enddate><creator>Nomiyama, Takashi</creator><creator>Akehi, Yuko</creator><creator>Takenoshita, Hiromasa</creator><creator>Nagaishi, Ryoko</creator><creator>Terawaki, Yuichi</creator><creator>Nagasako, Hisahiro</creator><creator>Kudo, Tadachika</creator><creator>Kodera, Takehiko</creator><creator>Kobayashi, Kunihisa</creator><creator>Urata, Hidenori</creator><creator>Yanase, Toshihiko</creator><general>Elsevier Ireland Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20120201</creationdate><title>Contributing factors related to efficacy of the dipeptidyl peptidase-4 inhibitor sitagliptin in Japanese patients with type 2 diabetes</title><author>Nomiyama, Takashi ; Akehi, Yuko ; Takenoshita, Hiromasa ; Nagaishi, Ryoko ; Terawaki, Yuichi ; Nagasako, Hisahiro ; Kudo, Tadachika ; Kodera, Takehiko ; Kobayashi, Kunihisa ; Urata, Hidenori ; Yanase, Toshihiko</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c419t-37613906c778740b7cb8399d1026554ea784d03409b891b12eba217e28d18da3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Asia - epidemiology</topic><topic>Asian Continental Ancestry Group - statistics & numerical data</topic><topic>Biomarkers - blood</topic><topic>Body Mass Index</topic><topic>Diabetes Mellitus, Type 2 - blood</topic><topic>Diabetes Mellitus, Type 2 - drug therapy</topic><topic>Diabetes Mellitus, Type 2 - physiopathology</topic><topic>Diabetic Nephropathies - blood</topic><topic>Diabetic Nephropathies - drug therapy</topic><topic>Diabetic Nephropathies - physiopathology</topic><topic>Dipeptidyl-Peptidase IV Inhibitors - therapeutic use</topic><topic>Endocrinology & Metabolism</topic><topic>Female</topic><topic>Glycated Hemoglobin A - metabolism</topic><topic>Humans</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Pyrazines - therapeutic use</topic><topic>Sitagliptin Phosphate</topic><topic>Treatment Outcome</topic><topic>Triazoles - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Nomiyama, Takashi</creatorcontrib><creatorcontrib>Akehi, Yuko</creatorcontrib><creatorcontrib>Takenoshita, Hiromasa</creatorcontrib><creatorcontrib>Nagaishi, Ryoko</creatorcontrib><creatorcontrib>Terawaki, Yuichi</creatorcontrib><creatorcontrib>Nagasako, Hisahiro</creatorcontrib><creatorcontrib>Kudo, Tadachika</creatorcontrib><creatorcontrib>Kodera, Takehiko</creatorcontrib><creatorcontrib>Kobayashi, Kunihisa</creatorcontrib><creatorcontrib>Urata, Hidenori</creatorcontrib><creatorcontrib>Yanase, Toshihiko</creatorcontrib><creatorcontrib>members of CHAT</creatorcontrib><creatorcontrib>CHAT</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Diabetes research and clinical practice</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Nomiyama, Takashi</au><au>Akehi, Yuko</au><au>Takenoshita, Hiromasa</au><au>Nagaishi, Ryoko</au><au>Terawaki, Yuichi</au><au>Nagasako, Hisahiro</au><au>Kudo, Tadachika</au><au>Kodera, Takehiko</au><au>Kobayashi, Kunihisa</au><au>Urata, Hidenori</au><au>Yanase, Toshihiko</au><aucorp>members of CHAT</aucorp><aucorp>CHAT</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Contributing factors related to efficacy of the dipeptidyl peptidase-4 inhibitor sitagliptin in Japanese patients with type 2 diabetes</atitle><jtitle>Diabetes research and clinical practice</jtitle><addtitle>Diabetes Res Clin Pract</addtitle><date>2012-02-01</date><risdate>2012</risdate><volume>95</volume><issue>2</issue><spage>e27</spage><epage>e28</epage><pages>e27-e28</pages><issn>0168-8227</issn><eissn>1872-8227</eissn><cop>Ireland</cop><pub>Elsevier Ireland Ltd</pub><pmid>21899912</pmid><doi>10.1016/j.diabres.2011.08.016</doi></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0168-8227 |
| ispartof | Diabetes research and clinical practice, 2012-02, Vol.95 (2), p.e27-e28 |
| issn | 0168-8227 1872-8227 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_919226555 |
| source | MEDLINE; Elsevier ScienceDirect Journals Complete |
| subjects | Adult Aged Asia - epidemiology Asian Continental Ancestry Group - statistics & numerical data Biomarkers - blood Body Mass Index Diabetes Mellitus, Type 2 - blood Diabetes Mellitus, Type 2 - drug therapy Diabetes Mellitus, Type 2 - physiopathology Diabetic Nephropathies - blood Diabetic Nephropathies - drug therapy Diabetic Nephropathies - physiopathology Dipeptidyl-Peptidase IV Inhibitors - therapeutic use Endocrinology & Metabolism Female Glycated Hemoglobin A - metabolism Humans Male Middle Aged Pyrazines - therapeutic use Sitagliptin Phosphate Treatment Outcome Triazoles - therapeutic use |
| title | Contributing factors related to efficacy of the dipeptidyl peptidase-4 inhibitor sitagliptin in Japanese patients with type 2 diabetes |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-19T22%3A14%3A53IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Contributing%20factors%20related%20to%20efficacy%20of%20the%20dipeptidyl%20peptidase-4%20inhibitor%20sitagliptin%20in%20Japanese%20patients%20with%20type%202%20diabetes&rft.jtitle=Diabetes%20research%20and%20clinical%20practice&rft.au=Nomiyama,%20Takashi&rft.aucorp=members%20of%20CHAT&rft.date=2012-02-01&rft.volume=95&rft.issue=2&rft.spage=e27&rft.epage=e28&rft.pages=e27-e28&rft.issn=0168-8227&rft.eissn=1872-8227&rft_id=info:doi/10.1016/j.diabres.2011.08.016&rft_dat=%3Cproquest_cross%3E919226555%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=919226555&rft_id=info:pmid/21899912&rft_els_id=S016882271100461X&rfr_iscdi=true |